PROSCAR is indicated for the treatment and control of benign prostatic hyperplasia (BPH) and for the prevention of urologic events to: Reduce the risk of acute urinary retention.
Reduce the risk of surgery including transurethral resection of the prostate (TURP) and prostatectomy.
PROSCAR causes regression of the enlarged prostate, improves urinary flow and improves the symptoms associated with BPH.
Patients with an enlarged prostate are the appropriate candidates for therapy with PROSCAR.
PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed 4 point increase in AUA symptom score).